

**Opto Circuits' subsidiary launches next generation drug eluting stent  
in world markets  
Receives CE approval for TAXCOR Plus™**

**Bengaluru, 5<sup>th</sup> January 2010**

Opto Circuits (India) Ltd's wholly-owned subsidiary Eurocor GmbH has received CE (Communit  European) mark approval for marketing and sale of its novel drug-eluting stent - TAXCOR Plus™. TAXCOR Plus™ is on a Cobalt Chromium platform with stent struts of 0.0025, which are the thinnest struts available in the industry. It has Paclitaxel drug (1µg/mm<sup>2</sup>) and the carrier for the drug is Shellac (US FDA /EMEA approved) which helps in the uniform distribution of the drug across the culprit lesion.

Explaining the distinctive technology of this system, Vinod Ramnani, Chairman & Managing Director, OCI, said, "Most drug-eluting stents available in the market have a polymer coating to keep the drug intact on the stent struts. However, in certain group of patients, Polymer coatings on DES result in inflammatory response and delay in SAT (sub-acute Thrombosis). TAXCOR Plus™ is backed by years of research and has shown excellent clinical results as seen with DIOR® (Eurocor's drug-eluting balloon) & is based on a Cobalt Chromium stent platform."

TAXCOR Plus™ provides unique therapeutic benefits to patients requiring Drug Eluting Stents for Coronary Angioplasty. The thinnest stent struts (low profile) result in superior deliverability to culprit lesion as against the other products available in the market. Its Shellac coating helps in uniform distribution of drug across such lesions.